宝莱特：独立董事对相关事项的独立意见 广东宝莱特医用科技股份有限公司 独立董事对相关事项的独立意见 我们作为广东宝莱特医用科技股份有限公司（以下简称"公司"）的独立董 事，根据《关于在上市公司建立独立董事制度的指导意见》、《上市公司治理准 则》等有关文件规定，以及《公司章程》、《独立董事工作制度》等公司制度的 约定，本着对公司、全体股东和投资者负责的态度，秉持实事求是的原则，对公 司第八届董事会第八次会议的相关事项发表如下独立意见： 一、 关于募投项目延期、调整部分募投项目募集资金投入金额及内部投资结 构、变更部分募投项目实施方式的独立意见 独立董事认为，本次募集资金调整事项是经公司综合论证了外部市场环境、 项目实施需求及项目建设进展，结合公司发展战略、经营需要及业务拓展需求作 出的审慎决定，不会对公司当前募投项目实施和生产经营造成不利影响，不存在 改变或变相改变募集资金投向和其他损害股东利益的情形。本次事项履行了必要 的法定程序，符合有关法律法规、规范性文件的规定。全体独立董事一致同意该 事项并将本议案提交公司 2023 年第一次临时股东大会审议。 二、 关于调整 2021 年限制性股票激励计划授予价格及授 ...

一、本次激励计划已履行的审批程序 1、2020年12月31日，公司召开第七届董事会第十二次会议，审议通过了《关 于<公司2021年限制性股票激励计划（草案）>及其摘要的议案》、《关于<公司 2021年限制性股票激励计划实施考核管理办法>的议案》、《关于提请股东大会 授权董事会办理2021年限制性股票激励计划相关事宜的议案》。公司独立董事就 本激励计划相关事项发表了独立意见，并公开征集投票权。广东精诚粤衡律师事 务所出具了法律意见书，珠海市德永管理咨询有限公司就本次股权激励计划出具 了独立财务顾问报告。 2、2020年12月31日，公司召开第七届监事会第十二次会议，审议通过了《关 于<公司2021年限制性股票激励计划（草案）>及其摘要的议案》、《关于<公司 2021年限制性股票激励计划实施考核管理办法> 的议案》、《关于核实<公司2021 年限制性股票激励计划激励对象名单>的议案》。 3、公司已于2021年1月1日至2021年1月10日在内部对激励对象名单进行了公 示，在公示的时限内，没有任何组织或个人提出异议，无反馈记录。监事会对激 励计划授予激励对象名单进行了核查，并于2021年1月14日出具了《监事会关于 ...

证券代码：300246 证券简称：宝莱特 公告编号：2023-069 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于调整 2021 年限制性股票激励计划授予价格及授予数量的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2023 年 9 月 5 日召开第八届董事会第八次会议、第八届监事会第七次会议审议通过了《关于调 整 2021 年限制性股票激励计划授予价格及授予数量的议案》，现将有关事项说 明如下： 一、本次激励计划已履行的审批程序 1、2020年12月31日，公司召开第七届董事会第十二次会议，审议通过了《关 于<公司2021年限制性股票激励计划（草案）>及其摘要的议案》、《关于<公司 2021年限制性股票激励计划实施考核管理办法>的议案》、《关于提请股东大会 授权董事会办理2021年限制性股票激励计划相关事宜的议案》。公司独立董事就 本激励计划相关事项发表了独立意见，并公开征集投票权。广东精诚粤衡律师事 务所出具了法律意见书，珠海市德永管理咨询有限公司就本次股权激 ...

广东宝莱特医用科技股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押展期的基本情况 广东宝莱特医用科技股份有限公司（以下简称"公司"）于近日接到公司控 股股东、实际控制人燕金元先生办理部分股份质押展期相关手续的通知，具体事 项如下： 证券代码：300246 证券简称：宝莱特 公告编号：2023-063 债券代码：123065 债券简称：宝莱转债 注：上述股份限售数量为高管锁定股份。截至2023年9月1日公司的股本总数为263,683,857 股计算占总股本比例。 三、控股股东及其一致行动人的股份质押展期情况说明 1、本次质押展期主要基于控股股东、实际控制人个人资金安排，未形成新 的股份质押，不涉及新增融资安排，不存在用于满足上市公司生产经营相关需求 的情况。 2、截至本公告日，上述控股股东及其一致行动人资信状况良好，质押的股 票不存在强制平仓的情形。若后续出现平仓风险，燕金元先生将采取包括但不限 于提前购回、补充质押等方式应对平仓风险，公司将按规定及时履行信息披露义 务，敬请投资者注意投资风险。 四、 ...

债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 证券代码：300246 证券简称：宝莱特 公告编号：2023-061 关于宝莱转债 2023 年付息的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 6、"宝莱转债"本次付息的债权登记日为 2023 年 9 月 1 日，截止至 2023 年 9 月 1 日下午深圳证券交易所收市后，在中国证券登记结算有限责任公司深圳分公 司（以下简称"中国结算深圳分公司"）登记在册的"宝莱转债"持有人享有本次派 发的利息，在 2023 年 9 月 1 日前（含当日）申请转换成公司股票的可转换公司 债券，公司不再向其持有人支付本计息年度及以后计息年度的利息。 特别提示： 1、"宝莱转债"（债券代码：123065）将于 2023 年 9 月 4 日支付第三年利息， 每 10 张"宝莱转债"（面值 1,000 元）利息为 10.00 元（含税）。 2、债权登记日：2023 年 9 月 1 日 3、除息日：2023 年 9 月 4 日 4、付息日：2023 年 9 月 4 日 5、本次付息期间及票面利率：计息 ...

本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示 1.案件所处的诉讼阶段：收到法院诉讼材料，尚未开庭。 2.上市公司所处当事人地位：被告。 3.涉案的金额：案件一 1,000 万元、案件二 1,000 万元、案件三 1,000 万元。 债券代码：123065 债券简称：宝莱转债 证券代码：300246 证券简称：宝莱特 公告编号：2023-057 广东宝莱特医用科技股份有限公司 关于涉及诉讼的公告 债券代码：123065 债券简称：宝莱转债 4.对上市公司损益产生的影响：案件尚未开庭审理，对公司本期利润或期后 利润的影响存在不确定性。 广东宝莱特医用科技股份有限公司（以下简称"公司"或"宝莱特公司"）于 近日收到福建省福州市中级人民法院送达的传票及《民事起诉状》｛（2023）闽 01 民初 936 号、（2023）闽 01 民初 937 号、（2023）闽 01 民初 938 号｝等法 律文书，截至本公告披露日，该案件已立案受理尚未开庭审理。 一、诉讼的基本情况 案件一：案号为（2023）闽 01 民初 936 号 原告：深圳迈瑞生物医疗电子股份有限公司（ ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230701 特定对象调研 分析师会议 投资者关系活 媒体采访 业绩说明会 动类别 新闻发布会 路演活动 现场参观 其他 时间 2023 年 7 月 28 日、2023 年 7 月 31 日 地点 进门财经、腾讯会议 参与单位名称 光大证券、申万宏源证券、上海证券、华鑫证券等 85 家机构（详情见附 后的参会名单） 上市公司接待 董事会秘书兼副总裁杨永兴先生，财务总监许薇女士，证券事务代表李韵 人员姓名 妮女士，证券事务专员钟欣昊先生。 公司介绍环节： 投资者关系活 宝莱特成立于 1993 年，主营业务为医疗器械产品的研发、生产、销 动主要内容介 售，主要涵盖健康监测与血液净化两大业务板块。公司作为中国最早一批 绍 研发制造医疗监护仪的民族企业，是监护仪产品线最完善的公司之一，是 国家发改委授予的"国家多参数监护仪产业化基地"，目前公司的监护设备 已覆盖数千家医疗机构。 公司监护类产品品类丰富，拥有一体式监护仪、插件式监护仪和掌上 监护仪三大系列产品，涵盖了急危重症监护、亚重症监护、手术麻醉监护、 新生儿及 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥665.23 million, representing a 19.22% increase compared to ¥557.99 million in the same period last year[22]. - Net profit attributable to shareholders reached approximately ¥58.86 million, a significant increase of 728.20% from ¥7.11 million in the previous year[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥44.40 million, up 1,072.95% from ¥3.79 million year-on-year[22]. - Basic earnings per share increased to ¥0.3091, reflecting a 639.47% rise compared to ¥0.0418 in the same period last year[22]. - Total assets at the end of the reporting period were approximately ¥2.62 billion, an increase of 7.34% from ¥2.44 billion at the end of the previous year[22]. - The company's cash flow from operating activities showed a net outflow of approximately ¥4.12 million, a decline of 106.42% compared to a net inflow of ¥64.15 million in the same period last year[22]. - The weighted average return on net assets was 4.08%, up from 0.53% in the previous year[22]. - The gross margin for the first half of 2023 improved to 45%, up from 40% in the same period last year[68]. Market Outlook - The medical device market in China is projected to reach approximately ¥1.5 trillion by 2025, with a compound annual growth rate of 20.04% from 2015 to 2020[36]. - The global medical device market is expected to reach about $595 billion by 2024, with a compound annual growth rate of 5.64%[35]. - The blood purification industry is projected to grow steadily, with the global dialysis market size increasing from €66.8 billion in 2015 to €82 billion in 2020, reflecting an annual growth rate of approximately 4%[39]. - The company anticipates continued growth in medical demand due to an aging population and increasing health awareness among the public[37]. - The market for hemodialysis equipment and consumables in China is projected to grow from 13.4 billion RMB in 2021 to 28.1 billion RMB by 2026, representing a compound annual growth rate of 18.6%[40]. Product Development and Innovation - The company emphasizes a strong focus on R&D, implementing a collaborative development process to ensure the conversion of technological innovations into results[32]. - The company launched several new products, including peritoneal dialysis equipment and electronic urine volume meters, focusing on smart monitoring solutions[52]. - The PD600 peritoneal dialysis device received its medical device registration certificate, featuring IoT capabilities for remote monitoring[53]. - The company added 45 new patents during the reporting period, including 5 invention patents, strengthening its innovation capabilities[55]. - The company is focusing on high-end product development and expanding its market presence in response to domestic medical device replacement opportunities[52]. Strategic Initiatives - The company operates primarily through a buyout distribution model domestically, enhancing brand influence while reducing market costs[31]. - The company maintains a centralized procurement model, leveraging a few high-quality suppliers to achieve significant price advantages[33]. - The company has established nine consumable bases and three channel platforms, positioning itself strongly in the blood purification market[46]. - The company is expanding its production capacity in Zhuhai and Suzhou, aiming to enhance its competitive edge in the blood purification industry[46]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[68]. Risk Management - The company has highlighted potential risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[3]. - The company is facing risks from national medical policy changes, particularly regarding blood dialysis and high-value medical consumables, which could impact revenue if alternative treatments receive more support[119]. - Rising raw material costs present a significant risk to profitability, prompting the company to invest in supply chain integration to control costs effectively[124]. - The competitive landscape in the blood dialysis market is intensifying, which may lead to price reductions and lower profit margins, posing risks to future profitability[122]. Corporate Governance and Social Responsibility - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company donated medical equipment to earthquake relief efforts in Turkey and has contributed over 8 million yuan to various charitable organizations[62]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[141]. - The company adheres to the ISO14001-2015 environmental management system standards to reduce emissions and energy consumption[141]. Shareholder Information - The total share capital increased from 174,814,904 shares to 175,680,734 shares following the stock incentive plan[136]. - The company has not disclosed any special voting rights or pledged shares among the top shareholders[182]. - The report indicates no changes in the number of shares held by major shareholders during the reporting period[182]. - The company maintains a diverse shareholder base, including both individual and institutional investors[182].

Group 1: Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices, primarily in life information and support as well as nephrology sectors [1] - The company is recognized as one of the earliest domestic manufacturers of medical monitors and has a comprehensive product line in this category, covering thousands of medical institutions [1][2] Group 2: Product Range - The company offers three major series of monitors, including critical care, sub-critical care, anesthesia monitoring, and neonatal care, applicable in various medical settings such as general wards, emergency rooms, ICUs, and operating rooms [2] - In the home healthcare sector, Baolait provides wearable medical products like pulse oximeters, ultrasound Doppler fetal heart monitors, temperature monitoring systems, and blood pressure monitors [2] Group 3: Financial Performance - In 2022, the company achieved a revenue of 1,183.70 million CNY, a year-on-year increase of 8.49%, with the blood purification segment contributing 787.14 million CNY, up by 16.77% [2] - For Q1 2023, the company reported a revenue of 344.57 million CNY, reflecting an 18.09% year-on-year growth, and a net profit of 27.16 million CNY, which is a significant increase of 94.75% [2] Group 4: Market Trends and Opportunities - The demand for medical monitoring equipment is expected to grow due to the increasing healthcare infrastructure needs and the rising number of medical institutions in China [3] - The domestic blood dialysis market presents significant opportunities for local brands, especially in dialysis equipment, as imported products no longer dominate the market [4] Group 5: R&D and Innovation - The company emphasizes innovation, holding 68 medical device registration certificates and 45 invention patents as of December 31, 2022 [2] - In 2022, R&D investment reached 90.63 million CNY, a 17.04% increase, with plans for steady growth in future R&D expenditures to support ongoing development [5]

Financial Performance - In 2022, the company achieved operating revenue of 118,369.97 million, a year-on-year increase of 8.49% [1] - The blood purification segment generated sales revenue of 78,713.70 million, growing by 16.77% [1] - The net profit attributable to shareholders decreased due to rising logistics costs, raw material prices, and increased sales and R&D expenses [1] - In 2022, total sales expenses reached 16,346.89 million, up 42.78% year-on-year; R&D expenses amounted to 8,754.33 million, increasing by 17.77% [2] 2023 Outlook - In Q1 2023, the company reported operating revenue of 34,456.58 million, an 18.09% increase year-on-year, and a net profit of 2,716.22 million, up 94.75% [2] - The company aims to focus on health monitoring and blood purification, targeting significant sales breakthroughs in peritoneal dialysis equipment and consumables [2] - The goal is to double the sales volume of dialysis devices and related products annually [2] Product Development and Market Strategy - The company offers a range of monitoring products, including integrated and modular monitors, widely used in various medical settings [2] - In the blood purification sector, the company has developed advanced dialysis machines and consumables, with a focus on domestic market growth and replacing imported products [3][4] - The D800Plus dialysis machine is noted for its innovative three-pump design, enhancing treatment effectiveness [3] Market Opportunities - The domestic blood dialysis market presents significant opportunities for local manufacturers, with less than 10% market share for fully domestic dialysis equipment [4] - The trend towards home-based automated peritoneal dialysis is expected to grow, supported by government policies and increasing patient adoption [4][5] Regional Production and Expansion - The company has established production bases for dialysis consumables across multiple regions, including Suzhou and Zhuhai, to enhance market reach and reduce transportation costs [5] - Recent acquisitions have strengthened the company's presence in the northwest region, with plans to expand production capacity and market coverage [5]